Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from ACADIA Pharmaceuticals ( (ACAD) ).
Acadia Pharmaceuticals Inc. announced the departure of Stephen R. Davis as CEO and his replacement by Catherine Owen Adams, effective September 23, 2024. Davis will receive a severance package and remain a consultant until potentially September 2025. Owen Adams, with a rich background in the biopharmaceutical industry and leadership roles at Bristol Myers Squibb and Johnson & Johnson, is set to lead Acadia with a comprehensive compensation plan that includes a $900,000 base salary, performance bonuses, stock options, and additional benefits. Her appointment is part of a strategic move to harness her extensive experience in driving company growth and shareholder value.
For an in-depth examination of ACAD stock, go to TipRanks’ Stock Analysis page.
